April 29th 2024
Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.
February 1st 2024
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Trastuzumab Deruxtecan Shows Survival Improvement in HER2-positive Metastatic Breast Cancer
August 15th 2022Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.
Read More
Promising Findings From DESTINY-Breast04 Trial Energizes ASCO Meeting
July 22nd 2022Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.
Read More
Clinical Activity Found With Triplet Combination and ADCs in HER2-Mutant MBC
July 20th 2022Results from the SUMMIT basket study revealed encouraging results with the triplet regimen in patients with HR-positive/HER2-negative MBC compared with other variations and monotherapies of the 3 drugs.
Read More
Pertuzumab-Based Regimen Shows Continued Benefit in HER2-Positive Breast Cancer
July 15th 2022Findings from the phase 3 APHINITY study show that the combination pertuzumab, trastuzumab, and chemotherapy improves invasive disease-free survival compared with trastuzumab and chemotherapy alone in patients with lymph node-positive, HER2-positive early breast cancer.
Read More
FDA Accepts BLA for [Vic-] Trastuzumab Duocarmazine as HER2+ mBC Treatment
July 12th 2022Based on findings from the TULIP study, [vic-] trastuzumab duocarmazine may be a new standard treatment option for patients with HER2-positive unresectable locally advanced metastatic breast cancer. a biologics license application has been accepted by the FDA.
Read More
Tucatinib Added to First-Line Maintenance Under Investigation in HER2+ Metastatic Breast Cancer
June 9th 2022The addition of tucatinib to standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer will be examined in the ongoing phase 3 HER2CLIMB-05 trial.
Read More
DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast Cancer
June 4th 2022A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
Read More
Sacituzumab Govitecan Sustains Efficacy Across HER2 Expressions in TNBC
May 6th 2022Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.
Read More
Positive Survival Outcomes With/ Without Paclitaxel in Patients With HER2+ Breast Cancer
May 5th 2022Survival rates for patients with different subtypes of early breast cancer who had a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel are promising.
Read More
Pyrotinib/Capecitabine Shows Activity in HER2-Positive Breast Cancer with Brain Metastases
March 10th 2022Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.
Read More
FDA Grants Priority Review to Fam-Trastuzumab Deruxtecan-Nxki for HER2+ mBC
January 17th 2022The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.
Read More